Clinical Trial: Detecting Early Onset Pre-eclampsia and Use of Placental Growth Factor (PlGF) for Marker of Trisomy 21

Study Status: Terminated
Recruit Status: Terminated
Study Type: Observational

Official Title: Study for the Evaluation of the Benefits of 1 st Trimester Risk Markers in Detecting Early Onset Pre-eclampsia and the Use of the Placental Growth Factor (PlGF) as a Potential Marker for This is a study for the evaluation of the benefits of 1 st Trimester risk markers in detecting Early Onset Pre-eclampsia and the use of the Placental Growth factor(PIGF) as a potential marker for Trisomy 21 and other aneuploidies.

Aim of this prospective nonprofit study is to analyze the benefits of early onset pre eclampsia risk assessment in the 1st trimester (measuring biochemical markers [PIGF], blood pressure and Doppler ultrasound), and how the results can permit to modify or influence the course of the preeclampsia during the pregnancy. The investigators will also evaluate the potential use of the PIGF as a marker to improve the prenatal screening with the currently used nuchal translucency, serum Pregnancy-associated plasma protein A (PAPP-A) and free beta subunit of human chorionic gonadotropin (fBhCG) parameters.

Detailed Summary:
Sponsor: OVO R & D

Current Primary Outcome: levels of Placental Protein 13 (PP13) , PIGF, PAPP-A, PIBF [ Time Frame: 6-13.6 wks gestation ]

Original Primary Outcome: levels of PP13, PIGF, PAPP-A [ Time Frame: 6-13.6 wks gestation ]

Current Secondary Outcome:

Original Secondary Outcome:

Information By: OVO R & D

Dates:
Date Received: January 31, 2011
Date Started: June 2012
Date Completion:
Last Updated: July 24, 2015
Last Verified: July 2015